These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 21545850)

  • 1. B cells in systemic sclerosis: a possible target for therapy.
    Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
    Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
    Hasegawa M
    J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
    Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
    Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
    Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Korfiatis P; Yiannopoulos G; Andonopoulos AP
    Semin Arthritis Rheum; 2010 Oct; 40(2):127-36. PubMed ID: 20004954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic roles of B lymphocytes in systemic sclerosis.
    Yoshizaki A
    Immunol Lett; 2018 Mar; 195():76-82. PubMed ID: 29307688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New developments in the pathogenesis of systemic sclerosis.
    Sakkas LI
    Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets.
    Yoshizaki A
    J Dermatol; 2016 Jan; 43(1):39-45. PubMed ID: 26782005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.
    Hasegawa M; Takehara K
    Semin Arthritis Rheum; 2012 Dec; 42(3):281-96. PubMed ID: 22542279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunobiology of systemic sclerosis.
    Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
    Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.
    Hasegawa M; Hamaguchi Y; Yanaba K; Bouaziz JD; Uchida J; Fujimoto M; Matsushita T; Matsushita Y; Horikawa M; Komura K; Takehara K; Sato S; Tedder TF
    Am J Pathol; 2006 Sep; 169(3):954-66. PubMed ID: 16936269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.
    Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD
    Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
    Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
    Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast abnormalities in the pathogenesis of systemic sclerosis.
    Usategui A; del Rey MJ; Pablos JL
    Expert Rev Clin Immunol; 2011 Jul; 7(4):491-8. PubMed ID: 21790292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis.
    Tsuchiya N; Kuroki K; Fujimoto M; Murakami Y; Tedder TF; Tokunaga K; Takehara K; Sato S
    Arthritis Rheum; 2004 Dec; 50(12):4002-7. PubMed ID: 15593213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells.
    Sato S; Fujimoto M; Hasegawa M; Takehara K
    Arthritis Rheum; 2004 Jun; 50(6):1918-27. PubMed ID: 15188368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial/lymphocyte activation leads to prominent CD4+ T cell infiltration in the gastric mucosa of patients with systemic sclerosis.
    Manetti M; Neumann E; Müller A; Schmeiser T; Saar P; Milia AF; Endlicher E; Roeb E; Messerini L; Matucci-Cerinic M; Ibba-Manneschi L; Müller-Ladner U
    Arthritis Rheum; 2008 Sep; 58(9):2866-73. PubMed ID: 18759276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.